Becton, Dickinson and Company (BD), a global leader in medical technology, has officially announced the launch of its Elyra thulium fiber laser (TFL) system in the United States. This strategic release marks a significant expansion of the company’s urological portfolio, specifically targeting the complex and high-volume field of kidney stone management. By integrating advanced TFL technology with a design philosophy centered on clinician feedback and operational efficiency, BD aims to redefine the standards of care for lithotripsy and soft tissue surgical interventions.
Main Facts: A New Paradigm in Urologic Laser Technology
The Elyra platform represents a shift in how urologists approach the fragmentation and removal of renal calculi. Available in two distinct configurations—Elyra and Elyra Plus—the system is designed to provide surgical teams with the flexibility to select the power and performance capabilities that align with their specific hospital protocols and clinical requirements.
At its core, the Elyra system utilizes thulium fiber laser (TFL) technology, which has gained significant traction in the medical community for its efficiency in stone lithotripsy. Compared to traditional Holmium:YAG lasers, TFL systems are often praised for their ability to deliver finer dust, reduced retropulsion (the movement of stones during laser application), and greater versatility in handling various stone compositions.
The physical design of the Elyra system addresses long-standing pain points in the operating room. Traditional laser systems are frequently criticized for their large footprint, the necessity for specialized water cooling, and cumbersome startup sequences. The Elyra system mitigates these issues with an air-cooled design and a compact, ergonomic frame that facilitates easier integration into modern, often space-constrained operating theaters. Furthermore, the platform features a streamlined, intuitive user interface, a rapid startup sequence, and highly customizable settings, all aimed at reducing the cognitive and physical load on the surgical team.
Chronology: From Development to Clinical Implementation
The introduction of the Elyra system is the culmination of a focused development cycle aimed at closing the gaps in current stone management workflows. While the official US launch was announced in May 2026, the pathway to this milestone involved rigorous testing and early-stage clinical validation.
Initial clinical procedures were successfully performed using the Elyra Plus TFL system at a premier medical center. These early trials served as a crucial proving ground, where urologists and operating room technicians evaluated the system’s performance in real-world scenarios. Feedback from these sessions highlighted the device’s accessible interface and integrated safety functions, both of which were cited as primary contributors to the "operational ease" experienced during complex procedures.
This launch follows a period of aggressive expansion for BD’s urology division. Earlier in the same month, BD made headlines through a strategic partnership with the Wellstar Health System, aimed at optimizing medication delivery. While the Wellstar collaboration focused on pharmacy-to-bedside safety through the integration of BD Pyxis and Alaris systems, the proximity of these announcements underscores a broader corporate strategy: leveraging internal innovation and external partnerships to digitize and streamline hospital infrastructure across multiple clinical departments.
Supporting Data: Why TFL is Changing the Landscape
The shift toward TFL technology, as exemplified by the Elyra system, is supported by a growing body of clinical evidence favoring fiber-based lasers over traditional solid-state lasers.
The Advantages of TFL Technology:
- Reduced Retropulsion: One of the most significant challenges in laser lithotripsy is the displacement of the stone during treatment. TFL systems generally offer lower retropulsion, allowing surgeons to keep the stone in place more effectively, which reduces procedure time and increases the success rate of complete fragmentation.
- Superior Dusting: The Elyra system’s ability to create finer particles facilitates the "dusting" technique, where stones are reduced to a fine powder that can be passed spontaneously by the patient, often eliminating the need for basket retrieval.
- Energy Efficiency: The air-cooled nature of the Elyra platform signifies a move away from the high-maintenance requirements of water-cooled systems, which require complex plumbing and heat exchange infrastructure in the OR.
- Safety and Customization: By allowing clinicians to fine-tune energy delivery settings, the Elyra system helps in minimizing collateral damage to surrounding soft tissue, a critical factor in safe ureteroscopic interventions.
Official Responses and Strategic Vision
The leadership at BD has positioned the Elyra platform as a cornerstone of their future urology strategy. Mike Cusack, President of BD’s Urology and Critical Care division, emphasized that the product is a testament to the company’s commitment to "speed and purpose."
"Elyra demonstrates how BD innovates with speed and purpose, introducing technology that helps clinicians deliver high-quality care more efficiently," Cusack stated. "By pairing advanced TFL technology with a clinician-focused design, Elyra streamlines kidney stone care and supports greater adaptability across diverse procedural needs."
The "clinician-focused design" is not merely marketing rhetoric; it addresses a reality in modern healthcare where OR staff turnover and the complexity of new equipment can lead to procedural delays. By simplifying the startup and customization process, BD is betting that hospitals will prioritize the Elyra system not just for its clinical outcomes, but for its impact on overall surgical throughput.
Furthermore, the company has indicated that the Elyra platform was engineered with modularity in mind. It is designed to allow for future software and hardware enhancements, ensuring that the system remains responsive to evolving clinical requirements and technological advancements in the years to come.
Implications for the Future of Stone Management
The launch of the Elyra system has broad implications for the urology sector, particularly regarding the concept of "holistic stone management." BD is not positioning Elyra as an isolated tool, but as a component of a comprehensive ecosystem.
The Elyra lineup is designed to coordinate seamlessly with BD’s existing portfolio, which includes products for access, dilation, visualization, fragmentation, removal, and drainage. By offering a "one-stop-shop" approach to urologic surgery, BD aims to reduce the vendor-fragmentation often seen in hospital supply chains. This consolidation allows for more standardized procedures, easier training for OR staff, and, potentially, better cost control for healthcare facilities.
Impact on Clinical Practices:
- Operational Efficiency: Hospitals that adopt the Elyra system may see reduced "turnover time" between procedures due to the faster startup sequence and the elimination of specialized cooling requirements.
- Training and Adoption: The user-friendly interface is designed to lower the learning curve for new surgeons and residents, potentially speeding up the adoption of TFL technology in smaller or mid-sized hospitals.
- Patient Outcomes: Through increased control over lithotripsy parameters, surgeons can provide more tailored treatment plans, potentially leading to fewer complications and shorter recovery times for patients suffering from kidney stones.
- Market Competition: The entry of a major player like BD into the TFL market with a focus on both high-end (Plus) and standard (Elyra) versions intensifies competition with existing laser manufacturers, which will likely drive further innovation and potential price competitive-ness in the sector.
Conclusion
The release of the Elyra thulium fiber laser system marks a pivotal moment for BD as it deepens its footprint in the surgical urology market. By blending technical prowess with a deep understanding of the operating room environment, BD is addressing the dual demands of clinical efficacy and operational excellence. As the healthcare industry continues to move toward more integrated, efficient, and technology-driven surgical solutions, the Elyra system stands as a clear indicator of where the future of kidney stone management is headed. With the backing of a robust product ecosystem and a focus on modular growth, BD is well-positioned to influence the standard of care for urologists across the United States.
About the Author
